Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
1. HC Wainwright initiates coverage of Septerna, suggesting a Buy rating. 2. Septerna's Native Complex Platform targets challenging drug discovery for GPCR therapies. 3. Partnership with Novo Nordisk valued and implications for pipeline development are noted. 4. Analyst highlights SEP-631's potential to replicate blockbuster drug effectiveness. 5. Current trading shows SEPN stock increased by 0.38% to $10.51.